Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Zevra Therapeutics Inc shares valued at $2,352 were purchased by Watton Corey Michael on Mar 28 ’25. At $7.84 per share, Watton Corey Michael acquired 300 shares. The insider’s holdings grew to 1,800 shares worth approximately $16326.0 following the completion of this transaction.
Also, Bode John B purchased 10,000 shares, netting a total of over 79,624 in proceeds. Following the buying of shares at $7.96 each, the insider now holds 40,000 shares.
Before that, Sangiovanni Timothy J. had sold 3,000 shares from its account. In a trade valued at $23,588, the SVP, Finance & Corp Controller traded Zevra Therapeutics Inc shares for $7.86 each. Upon closing the transaction, the insider’s holdings decreased to 3,000 shares, worth approximately $0.15 million.
Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in early October. As of September 24, 2024, Maxim Group has reiterated its “Buy” rating for ZVRA. Earlier on September 24, 2024, JMP Securities initiated its rating. Their recommendation was “a Mkt outperform” for ZVRA stock.
Analyzing ZVRA Stock Performance
On last trading session,, Zevra Therapeutics Inc [NASDAQ: ZVRA] rose 2.95% to $9.07. The stock’s lowest price that day was $8.71, but it reached a high of $9.14 in the same session. During the last five days, there has been a drop of approximately -3.30%. Over the course of the year, Zevra Therapeutics Inc shares have jumped approximately 8.75%. Shares of the company reached a 52-week high of $9.62 on 06/11/25 and a 52-week low of $6.19 on 04/09/25.
Support And Resistance Levels for Zevra Therapeutics Inc (ZVRA)
According to the 24-hour chart, there is a support level at 8.80, which, if violated, would cause prices to drop to 8.54. In the upper region, resistance lies at 9.24. The next price resistance is at 9.42. RSI (Relative Strength Index) is 57.99 on the 14-day chart, showing neutral technical sentiment.
Is Zevra Therapeutics Inc subject to short interest?
Stocks of Zevra Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 69168.0 shares to 5.67 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 5.6 million shares. A jump of 1.22% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.46 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.46.
Which companies own the most shares of Zevra Therapeutics Inc (ZVRA)?
In terms of Zevra Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 127.01% from the previous closing price of $8.81. Analysts anticipate Zevra Therapeutics Inc stock to reach 22 by 2025, with the lowest price target being 18. In spite of this, 7 analysts ranked Zevra Therapeutics Inc stock as Buy at the end of 2025. On April 02, 2024, Maxim Group assigned a price target of “a Buy” to the stock and reiterated coverage with a $18.
